Surufatinib - HUTCHMED
Alternative Names: HMPL-012; Sufatinib; Sulanda; Sulfatinib - HUTCHMEDLatest Information Update: 17 Jul 2024
At a glance
- Originator Hutchison MediPharma
- Developer Fujian Cancer Hospital; Hutchison MediPharma; HUTCHMED
- Class Antineoplastics; Indoles; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action Macrophage colony-stimulating factor receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neuroendocrine tumours
- Phase II/III Biliary cancer; Pancreatic cancer
- Phase II Colorectal cancer; Small cell lung cancer; Solid tumours; Thyroid cancer
- Phase I/II Soft tissue sarcoma
- Preclinical Non-small cell lung cancer
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from a phase II trial in Small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 08 May 2024 Phase-II/III clinical trials in Pancreatic cancer (Metastatic disease, Combination therapy, Late-stage disease, First-line therapy) in China (PO) (NCT06361888)
- 12 Apr 2024 Hutchmed plans a phase II/III for Pancreatic cancer (Combination therapy, Metastatic disease, First-line therapy, Late-stage disease) in China in May 2024 (NCT06361888)